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junction, and destabilization of the nicotinic acetylcholine receptors (nAChRs). One-third
of DMD patients also present non-progressive cognitive impairments. Considering the role
of the cholinergic system in cognitive functions, the number of nAChR binding sites and
the mRNA levels of a4, b2, and a7 subunits were determined in brain regions normally
enriched in dystrophin (cortex, hippocampus and cerebellum) of mdx mice using specific
ligands and reverse-transcription polymerase chain reaction assays, respectively. Mem-
brane preparations of these brain regions were obtained from male control and mdx mice
at 4 and 12 months of age. The number of [3H]-cytisine (a4b2) and [125I]-a-bungarotoxin
([125I]-aBGT, a7) binding sites in the cortex and cerebellum was not altered with age or
among age-matched control and mdx mice. A significant reduction in [3H]-cytisine (48%)
and [125I]-aBGT (37%) binding sites was detected in the hippocampus of mdx mice at 12
months of age. When compared with the age-matched control groups, the mdx mice did
not have significantly altered [3H]-cytisine binding in the hippocampus, but [125I]-aBGT
binding in the same brain region was 52% higher at 4 months and 20% lower at 12 months.
mRNA transcripts for the nAChR a4, b2, and a7 subunits were not significantly altered in
the same brain regions of all animal groups. These results suggest a potential alteration ofthe Elsevier OA license.
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b r a i n r e s e a r c h 1 4 8 3 ( 2 0 1 2 ) 9 6 – 1 0 4 97the nicotinic cholinergic function in the hippocampus of dystrophin-deficient mice, which
might contribute to the impairments in cognitive functions, such as learning and memory,
that have been reported in the dystrophic murine model and DMD patients.
& 2012 Elsevier B.V.Open access under the Elsevier OA license.1. Introduction
Duchenne muscle dystrophy (DMD) is an X-linked muscle
disease that manifests as a progressive and irreversible
muscle degeneration with a high incidence in boys (Emery,
2002). The myopathy is caused by mutations in the dystro-
phin gene resulting in a lack of protein expression (Hoffman
et al., 1987). One-third of DMD patients also present non-
progressive cognitive impairment, as well as behavioral and
neuropsychiatric disorders of variable intensities (Cyrulnik
et al., 2008; Hendriksen and Vles, 2008; Mehler, 2000).
Dystrophin is a 427-kDa protein expressed in striated mus-
cles and the central nervous system (CNS). It is localized at the
cytoplasmic face of the plasma membrane linking the intra-
cellular cytoskeleton with the extracellular matrix (Ervasti,
2007; Pilgram et al., 2010). Three full-length dystrophin (Dp427)
isoforms, which are transcribed from distinct promoters of the
DMD gene, are expressed in muscles (Dp427M), throughout the
brain (Dp427B), and in cerebellar Purkinje cells (Dp427P). Four
other shorter isoforms (Dp260, Dp140, Dp116, and Dp71),
regulated by internal promoters, are expressed in the CNS
and other tissues (Blake and Kroger, 2000; Perronnet and
Vaillend, 2010). The mutant mdx mouse is a well-studied
model of DMD that lacks the expression of full-length dystro-
phin in both themuscles and brain (Sicinski et al., 1989). At the
cell membrane, dystrophin is associated with a complex of
glycoproteins (DGC) comprised of dystroglycans, syntrophins,
dystrobrevins, sarcoglycans, and sarcospan (Blake et al., 2002;
Ervasti, 2007). In striated muscles, the lack of dystrophin
disrupts the macromolecular complex and damages the
plasma membrane, resulting in muscle degeneration and
necrosis (Petrof, 2002). At the neuromuscular synapse,
dystrophin and some components of the DGC are necessary
for the maturation of post-junctional folds and the regulation
of nicotinic acetylcholine receptors (nAChRs) (Ghedini et al.,
2008; Grady et al., 2000; Huh and Fuhrer, 2002). The protein
complex also plays a role in Ca2þ homeostasis and cell
signaling pathways involved in the maintenance of cell mem-
brane integrity (Batchelor and Winder, 2006).
In normal brains, dystrophin is abundant in the cerebral
cortex, hippocampus, cerebellum, and amygdala, where it is
located at postsynaptic densities of the neuronal synapses
(Lidov, 1996; Sakamoto et al., 2008; Sekiguchi et al., 2009).
In the hippocampus, cerebellum (Knuesel et al., 1999), and
amygdala (Sekiguchi et al., 2009) of the mdx mouse, the lack
of dystrophin and DGC has been shown to cause a reduction
in the size and number of GABAA receptor (GABAAR) clusters
containing the a1 and a2 subunits. A decrease in kainate-type
glutamate receptor density has also been described in differ-
ent brain regions of dystrophin-deficient mice (Yoshihara
et al., 2003). These observations suggest that dystrophin
and the DGC play a role in the stability of receptors and
synaptic function in the brain, indicating that cognitiveimpairment in the murine model and DMD patients might
be related to dysfunction in synaptic transmission (Perronnet
and Vaillend, 2010; Pilgram et al., 2010). Moreover, compared
with control animals, mdx mice have been shown to exhibit a
decreased response to nicotine in the passive avoidance test,
suggesting a possible downregulation of nAChRs in the CNS
(Coccurello et al., 2002). Decreased mRNA expression of the
a3 nAChR subunit has also been observed in the cortex and
hippocampus of mdx mice (Wallis et al., 2004), suggesting
possible dysfunctions in nicotinic cholinergic transmission in
the brain.
nAChRs are widely distributed in the brain, where they play
a role in cognitive functions, such as attention, memory and
learning. They are also involved in pathological conditions,
such as Alzheimer’s disease, Parkinson’s disease, schizophre-
nia, anxiety, depression, and epilepsy (Newhouse et al., 2004;
Sacco et al., 2004). These receptors are ligand-gated cationic
channels formed by the pentameric combination of different
a (a2–a10) and b (b2–b4) subunits expressed in the nervous
system (Dani and Bertrand, 2007). In the brain, the most
frequent nAChR subtypes are a4b2 (heteropentamers), which
bind nicotine with high affinity (Flores et al., 1992), and a7
(homopentamers), which bind nicotine with low affinity and
a-bungarotoxin with high affinity (Se´gue´la et al., 1993).
In view of the importance of the cholinergic system in
cognitive functions (Gold, 2003), which are impaired in some
DMD patients, the aim of this work was to quantify the
binding sites for a4b2 and a7 nAChRs subtypes and to
measure their mRNA levels in both whole brain tissue and
in brain regions normally enriched in dystrophin (i.e., the
cortex, hippocampus and cerebellum) of mdx mice. Consider-
ing that the progression of muscle disease in mdxmice is very
slow compared to that in DMD patients, and that behavioral
alterations and biochemical abnormalities in the brain are
more evident in older (46 months) mdxmice (Rae et al., 2002),
the analysis was conducted at two stages of muscle disease:
in young adults (4 months old), after maximal muscle degen-
eration has occurred (DiMario et al., 1991), and in old (12
months old) mdxmice, when the murine model exhibits some
features of the muscle disease (Pastoret and Sebille, 1995).2. Results
2.1. Binding sites for [3H]-cytisine
The specific binding of [3H]-cytisine to whole brain mem-
branes from control and mdx mice was saturable and repre-
sented 80–85% of total ligand binding. The number of
[3H]-cytisine binding sites (Bmax) in these membrane prepara-
tions decreased from 4 to 12 months of age by 20% in the
control, and by 35% in mdx mice. However, there were no
significant changes in the affinity of the ligand binding (Kd) in
Table 1 – Saturation binding of [3H]-cytisine and [125I]-a-bungarotoxin to whole brain membranes of 4- and 12-month-old
control and mdx mice.
Ligand 4-months 12-months
Control mdx Control mdx
[3H]-cytisine
Bmax (fmol/mg protein) 97.472.1 101.472.4 78.275.2
 65.873.3
Kd (nM) 1.1670.08 1.2770.09 1.5270.27 1.3370.18
[125I]-a-bungarotoxin
Bmax (fmol/mg protein) 46.973.9 49.573.9 51.575.4 77.4710.3
Kd (nM) 0.9070.17 1.0470.25 1.0070.18 1.1370.12
Data are means7SEM of three assays each in triplicate.
n Different from the 4-month-old group in a same animal strain (po0.05).
Fig. 1 – Specific binding of [3H]-cytisine in the cortex,
hippocampus, and cerebellum of 4- and 12- month-old
control and mdx mice. The data are given as the
means7SEM of three experiments repeated in triplicate.
po0.05 compared with the 4-month-old mdx group
(ANOVA and Tukey–Kramer’s post-hoc test).
Fig. 2 – Specific binding of [125I]-a-bungarotoxin ([125I]-aBGT)
in the cortex, hippocampus and cerebellum of 4- and 12-
month-old control and mdx mice. The data are given as the
means7SEM of three experiments repeated in triplicate.
po0.05, po0.001 compared to the age-matched control
group. ypo0.05 compared with the 4-month-old mdx group
(ANOVA and Tukey–Kramer’s post-hoc test).
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matched control groups, the Bmax and Kd values of [
3H]-
cytisine binding in the mdx brain membranes did not differ
at either age (Table 1).
In the cortex and cerebellum, there was no significant age-
related difference in the number of [3H]-cytisine binding sites
in either animal strain or between age-matched control
and mdx mice (Fig. 1). In the hippocampus, there was no
significant age-related difference in the number of [3H]-
cytisine binding sites in the control group; however, it
decreased by 48% with age in mdx mice from 4
(82.979.4 fmol/mg protein) to 12 (43.278.2 fmol/mg protein)
months (Fig. 1). When compared with age-matched control
groups, the number of [3H]-cytisine binding sites in the mdx
hippocampus did not differ at either age (Fig. 1). These results
indicated that the number of [3H]-cytisine binding sites
decreased with age in the hippocampal region of mdx mice,
and in whole brain preparations of control and mdx mice.2.2. Binding sites for [125I]-a-bungarotoxin ([125I]-aBGT)
The specific binding of [125I]-aBGT to whole brain membranes
from control and mdx mice was saturable and represented
90–95% of total ligand binding. The Bmax and Kd values of
[125I]-aBGT binding were not significantly altered with age ineither animal strain, and they did not differ between the age-
matched control and mdx mice at either age (Table 1).
In the cortex and cerebellum, the number of [125I]-aBGT
binding sites did not change from 4 to 12 months of age or
between the age-matched control and mdx mice (Fig. 2). In the
hippocampus, there were no age-related differences in [125I]-
aBGT binding in the control group; however, it was decreased by
37% with age in mdx mice from 4 (82.974.0 fmol/mg protein) to
12 (52.672.4 fmol/mg protein) months (Fig. 2). When compared
with age-matched control groups,mdxmice showed 52% higher
[125I]-BGT binding in the hippocampus at 4 months and 20%
lower binding at 12 months (Fig. 2). These results indicated that
[125I]-aBGT binding decreased with age in the hippocampus
of mdx mice and that [125I]-aBGT binding is altered in the
hippocampus of mdx mice when compared with age-matched
controls.
2.3. Relative quantification of a7, a4, and b2 nAChR
subunit mRNAs.
Fig. 3 shows the relative mRNA levels of a4, b2, and a7
nAChR subunits that were determined in the cortex,
hippocampus, and cerebellum of 4- and 12-month-old
control andmdxmice. In all three brain regions, no significant
difference was detected in the level of transcripts for a4, b2,
Fig. 3 – Representative semi-quantitative analysis of the relative abundance of the transcripts for the a4, a7, and b2 nAChR
subunits in the cortex, hippocampus and cerebellum from 4- and 12-month-old mdx compared with age-matched controls.
The data are expressed as the ratio of the densitometric measurement for each specific gene compared with the
corresponding internal standard (GAPDH) and presented as the means7SEM for three independent experiments.
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and mdx mice.3. Discussion
To investigate whether central cholinergic dysfunction is
associated with a lack of dystrophin, the number of
[3H]-cytisine and [125I]-aBGT binding sites and mRNAs levels
of a4, b2, and a7 nAChR subunits were determined inmembrane preparations from young (4 months old) and old
(12 months old) control and mdx mice. The brain regions
selected were those that are normally enriched in dystrophin,
i.e., the cortex, hippocampus, and cerebellum. The results
show that dystrophin-deficient mice exhibited significant
differences in the number of [3H]-cytisine (predominantly
a4b2 nAChRs) and [125I]-aBGT (a7 nAChRs) binding sites in the
hippocampus; this may be indicative of alterations in nico-
tinic cholinergic neurotransmission. Changes in the number
and function of nAChRs in various human brain regions have
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orders, such as Alzheimer’s disease, Parkinson’s disease,
schizophrenia, attention deficit hyperactivity disorder and
autism (Gotti et al., 2006; Guan et al., 2002; Sacco et al., 2004).
Similar cognitive impairments, as well as behavioral and
neuropsychiatric disorders have also been described in boys
with DMD (Hendriksen and Vles, 2008; Mehler, 2000). As the
data suggest these impairments might involve alterations in
nicotinic cholinergic function associated with a lack of
dystrophin in the brain.
The significant decrease in [3H]-cytisine binding sites
detected in the hippocampal region of old mdx mice was
consistent with those observed in whole brain membranes of
age-matched control and mdx groups, thus reflecting the
potential age-related reduction in the a4b2 nAChRs, as pre-
viously reported (Gahring et al., 2005). However, the decrease
in this receptor subtype was approximately two fold greater
in whole brain membrane preparations of old mdx mice
than in those from control, indicating that the absence of
dystrophin facilitates the age-related degenerative effects.
This observation was confirmed by the age-related reduction
in [125I]-aBGT binding sites obtained in the hippocampal
membranes of mdx mice, but not in the membranes from
control mice. These results are consistent with a disruption
in membrane stability being associated with age and lack of
dystrophin, as well as to an increase in choline-containing
compounds (glycerocholine and phosphocholine), as pre-
viously reported in the hippocampus and cerebellum of old
(46 months) mdx mice (Rae et al., 2002).
Several studies have shown the importance of dystrophin
and DGC in the anchoring and stabilization of receptors
and ionic channels (Connors et al., 2004; Pilgram et al.,
2010). The lack of dystrophin and DGC disrupts the cell
membrane structure, resulting in a reduction in the number
and size of GABAAR clusters in the hippocampus and cere-
bellum, where the protein is colocalized with these receptors
(Graciotti et al., 2008; Knuesel et al., 1999). Decrease in the
a3b2/b4 subtypes of nAChR in the superior cervical ganglion
(Del Signore et al., 2002; Di Angelantonio et al., 2011), frag-
mentation of the neuromuscular junction, and upregulation
of the embryonic-type nAChRs have also been reported in
dystrophin-deficient mice (Ghedini et al., 2008; Grady et al.,
2000; Huh and Fuhrer, 2002). Thus, it seems conceivable that
the structural disorganization of the cell membrane, asso-
ciated with a lack of dystrophin, might also be involved in the
altered number of [3H]-cytisine and [125I]-aBGT binding sites
observed in the hippocampus of mdx mice. With regard to the
number of a4b2 and a7 nAChR binding sites in mdx mice, the
hippocampus appears more responsive to the lack of dystro-
phin than the cortex and cerebellum do, as evidenced by the
fact that these regions normally express high levels of
dystrophin (Lidov, 1996); however, they did not present
marked changes in [3H]-cytisine and [125I]-aBGT binding.
A decrease in the mRNA expression of the a3 nAChR
subunit has been reported in the cortex and hippocampus
of young (o4 months) mdx mice (Wallis et al., 2004).
In contrast, the alterations in [3H]-cytisine and [125I]-aBGT
binding in the hippocampus of mdx mice observed in our
study were unaccompanied by significant changes in the
expression of a4, b2, and a7 transcripts, indicating that theeffects are related to post-transcriptional mechanisms. Simi-
lar observations have been reported for the cerebellum ofmdx
mice, in which a decrease in the number of GABAAR clusters
(Knuesel et al., 1999) was unrelated to changes in the
expression of the GABAAR a1-subunit, thereby indicating an
alteration in the receptor clustering rather than changes in
the receptor protein expression (Kueh et al., 2008). Our results
are unrelated to structural changes in the hippocampus of
mdx mice because there were no significant alterations
detected in the gross anatomy and no apparent signs of
neuronal loss or cellular pathology found in the same brain
region (Miranda et al., 2009). This is in contrast to findings
described for the cortex (Carretta et al., 2001; Sbriccoli et al.,
1995) and spinal trigeminal nucleus of the murine model
(Pinto et al., 2008).
The hippocampus is a brain structure involved in attention,
memory, and learning mechanisms in which functional a7,
a4b2, and a3b4 nAChR subtypes have been identified
(Alkondon and Albuquerque, 2004; Graham et al., 2003). These
receptors are expressed at presynaptic and postsynaptic sites
in GABAergic (inhibitory) and glutamatergic (excitatory)
neurons, and are involved in regulating neurotransmitter
release, mediating fast nicotinic synaptic transmission, and
modulating synaptic plasticity (Dani and Bertrand, 2007). a7
nAChRs predominate in the hippocampus, and their activa-
tion by endogenous ACh release or nicotinic agonists has been
shown to facilitate long-term synaptic potentiation, a form
of synaptic plasticity underlying learning and memory
(Drever et al., 2011; McKay et al., 2007). a7 nAChRs are also
densely expressed on GABAergic interneurons in the hippo-
campus, and their activation in vitro inhibits or disinhibits
GABAA synaptic activity on CA1 pyramidal neurons, thus
enhancing or suppressing synaptic potentiation (Alkondon
and Albuquerque, 2001; Ji et al., 2001). Our data show that the
[125I]-aBGT binding sites in the hippocampus were upregu-
lated in young and reduced in old mdx mice with respect to
their age-matched controls. The mechanisms underlying the
observed quantitative changes in the expression of a7 nAChRs
in the hippocampus of mdx mice are still unclear. However,
considering the influence of a7 nAChRs on GABAergic synap-
tic activity in the hippocampus (Albuquerque et al., 2009), it is
possible that the observed alterations in this receptor subtype
might reflect an adjustment of the excitatory–inhibitory
circuits in the hippocampal region, related to the decreased
number of GABAA receptors and the lack of dystrophin (Kueh
et al., 2008). Consistent with this hypothesis, we have recently
shown that [3H]-ACh release evoked by nAChR activation in
hippocampal synaptosomes was also significantly altered in
preparations from both young and old mdx mice compared
with those from their age-matched controls (Souccar et al.,
2011). These results indicate a potential nicotinic cholinergic
dysfunction in the hippocampus of dystrophin-deficient mice;
this dysfunction may in turn affect cognitive functions such
as learning and memory, both of which involving a4b2 and a7
nicotinic receptors (Levin et al., 2006). Indeed, deficits in
attention and memory, among other cognitive and behavioral
abnormalities, have been reported in boys with DMD
(Cyrulnik et al., 2008), whereas impaired consolidation of
certain forms of long-term memory with unaltered acquisi-
tion in learning tasks has been described in mdx mice
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reported an abnormal facilitation of N-methyl-D-aspartate
(NMDA) receptor-mediated synaptic transmission in the hip-
pocampal CA1 region of mdxmice, which has been attributed,
in part, to neuronal disinhibition associated with a reduced
number of GABAAR clusters and lack of dystrophin (Vaillend
and Billard, 2002; Vaillend et al., 2004). Nevertheless, the
functional role of the observed quantitative changes in a7
and a4b2 nAChRs in the disrupted NMDA receptor-mediated
synaptic plasticity in the hippocampus of mdx mice is still
unknown, and should be further evaluated.4. Conclusion
The absence of dystrophin alters the number of a7- and
b2-containing nAChRs in the hippocampal region of mdx
mice, thus supporting a role for dystrophin and DGC in
stabilizing these receptors in central synapses. The observed
quantitative changes of both nAChR subtypes in the hippo-
campus of mdx mice indicate that putative dysfunction of
nicotinic cholinergic synapses in the absence of dystrophin
might contribute to the impairment of cognitive functions,
such as learning and memory, that have been reported in
dystrophic mice and DMD patients.5. Experimental procedures
5.1. Animals
Normal (control) and mutant mdx 4- and 12-month-old male
mice from an C57Bl/10 strain that was bred in the Animal
Facility at the Instituto Nacional de Farmacologia e Biologia
Molecular, Escola Paulista de Medicina/Universidade Federal
de S ~ao Paulo were used. All animals were housed under a
controlled 12 h/12 h light/dark cycle and at 2272 1C with free
access to food and water. The animals were sacrificed using
cervical dislocation, and the brain was rapidly removed.
The cerebral cortex, hippocampus, and cerebellum were
dissected over a cold plate and frozen in liquid nitrogen. All
experiments were performed in accordance with the Guide for
the Care and Use of Laboratory Animals of the USA National
Institutes of Health (Bethesda, Maryland), and the local
Animal Investigation Ethical Committee approved all proce-
dures (Protocol # 1400/03).
5.2. Membrane preparation
The membranes from the whole brain, cerebral cortex,
hippocampus, and cerebellum of control and mdx mice were
prepared according to Davies et al. (1999). The brain regions
of 10 to 12 pooled animals were homogenized in 10 volumes
of ice-cold phosphate buffer (50 mM NaH2PO4; 50 mM
Na2HPO4; 1 mM EDTA; 0.1 mM PMSF; 0.01%(w/v) sodium
azide, pH 7.4) containing 0.32 M sucrose (Sigma Chemical
Co., St Louis, MO). The homogenate was centrifuged at 1,700 g
for 10 min at 4 1C, the pellet was re-suspended in 20 volumes
of sucrose buffer and re-centrifuged. The supernatant frac-
tions were combined, and the pellet was washed twice bycentrifugation (15,000 g, 4 1C, 30 min). The final pellet was re-
suspended in buffer, and the protein content was determined
using the Bradford (1976) method.
5.3. Ligand binding studies
Binding to a4b2 and a7 nAChR subtypes in the whole brain,
cortex, hippocampus, and cerebellum of control and mdx
mice was determined using the ligands [3H]-cytisine and
[125I]-a bungarotoxin ([125I]-aBGT), respectively
5.3.1. [3H]-cytisine binding assays
The analysis of the equilibrium binding of [3H]-cytisine to
whole brain membranes was performed as previously
described (Pabreza et al., 1991). The membrane samples
(0.1 mg) were incubated with [3H]-cytisine (specific activity
25 Ci/mmol, Perkin Elmer Inc., Waltham, MA) at concentra-
tions ranging from 0.1 nM to 5.0 nM for 75 min at 4 1C in a
buffer solution (50 mM Tris–HCl, 120 mM NaCl, 5 mM KCl,
4 mM CaCl2, 2 mM MgCl2, 1 mM EDTA, and 0.1 mM PMSF, pH
7.4) (Sigma) to a final volume of 0.5 ml. The number of
binding sites for [3H]-cytisine in the cerebral cortex, hippo-
campus, and cerebellum were measured using membrane
samples (0.1 mg) incubated with a saturating concentration
of the ligand (10 nM, final concentration) and 50 mM Tris–HCl
buffer for 75 min at 4 1C. Non-specific binding was deter-
mined in the presence of 10 mM nicotine (Sigma). The specific
binding was determined as the total binding minus the
nonspecific binding. The incubations were terminated using
vacuum filtration through A/E glass fiber filters pre-soaked in
0.05%(v/v) polyethyleneimine. The filters were washed twice
with ice-cold buffer, and the radioactivity was counted in a
scintillation beta counter (Packard Instruments Co., Meriden,
Connecticut).
5.3.2. [125I]-aBGT binding assays
Saturation binding experiments for [125I]-aBGT were per-
formed using whole brain membranes (0.1 mg protein) incu-
bated in triplicate with 0.1 nM to 10 nM [125I]-aBGT (specific
activity 200 mCi/mmol, Amersham Biosciences, U.K.) in 0.5 ml
phosphate buffer (final volume), for 120 min at 25 1C.
The [125I]-aBGT binding sites for the cortex, hippocampus,
and cerebellum were determined by incubating the mem-
brane samples (0.1 mg) from each structure with 10 nM [125I]-
aBGT (final concentration) in phosphate buffer for 30 min at
25 1C. The non-specific binding was determined using sam-
ples containing 1 mM unlabeled toxin. The incubations were
terminated with the addition of 1 ml ice-cold phosphate-
buffered saline containing 0.5% BSA followed by centrifuga-
tion (15,000 g, 20 min, 4 1C). This step was repeated, and
samples were washed overnight in the buffer solution at
4 1C. Subsequently, the samples were centrifuged and the
radioactivity in the pellet was determined using a gamma
counter (Packard Instruments Co., Meriden, Connecticut).
5.4. Reverse-transcription polymerase chain reaction (RT-
PCR)
Total RNA was extracted from the cortex, hippocampus and
cerebellum using Trizols reagent (Invitrogen, San Diego, CA)
Table 2 – Primer sequences used for the amplification of each transcript coding for nAChR subunits (a4, a7, and b2) and
internal control GAPDH, corresponding base sites, and the sizes of PCR products (D). Each set of primers spans at least one
intron to ensure that the PCR products were from cDNA and not genomic DNA.
Gene Primer Oligonucleotide sequence (50–30) Nucleotide position D ( bp)
a4 Forward cagcttccagtgtcagacca 1668–1687 395
Reverse tggaagatgtgggtgactga 2043–2062
a7 Forward cattccacaccaacgtcttg 414–433 357
Reverse tgagcacacaaggaatgagc 751–770
b2 Forward gtaccgctggtgggaaagta 1059–1078 472
Reverse tccaatcctccctcacactc 1511–1530
Gapdh Forward ggaagctggtcatcaacggg 258–277 357
Reverse ggcagtgatgccatggactg 595–614
GenBank accession numbers: NM_015730 (a4); NM_007390 (a7); NM_009602 (b2); and X02231 (Gapdh).
b r a i n r e s e a r c h 1 4 8 3 ( 2 0 1 2 ) 9 6 – 1 0 4102according to the manufacturer’s instructions. The RNA (1 mg)
was reverse-transcribed using 3 U of ThermoScript reverse
transcriptase (Invitrogen) and oligo d(T)20 primers. The reac-
tion was performed in a solution containing 50 mM Tris
acetate (pH 8.4), 75 mM KOAc, 8 mM Mg (AOC)2, 5 mM DTT,
1 mM dNTPs and 40 U of RNAse inhibitor at 55 1C for 1 h. The
amplification was performed in a thermal cycler (Applied
Biosystems, Foster City, CA) with 1 ml of the cDNA in 20 ml of
buffer containing 1.5 mM MgCl2, 0.2 mM dNTPs, 2 U of Taq
DNA polymerase (Invitrogen) and 0.4 mM of each sense- and
antisense-specific primer to amplify the specific nucleotide
sequences present in the nAChR subunit (a4, a7, and b2) and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH; used as
internal control) gene transcripts (Table 2). The PCR cycling
conditions for the amplification of each transcript in the
linear range and analysis of final DNA products on an agarose
gel containing ethidium bromide (0.5 mg/ml) were conducted
as previously described (Ghedini et al. 2008). The gel photo-
graphs were scanned and the results were quantified using
Scion Image Analysis (Scion Corporation, Frederick, Mary-
land) for the densitometric analysis. The data were normal-
ized against that of the GAPDH mRNA in each sample.
5.5. Statistical analysis
The data were presented as the means7SEM values.
The saturation binding data for both ligands were analyzed
using nonlinear regression. The differences between the control
and mdx groups were determined using one-way analysis of
variance (ANOVA) followed by the Tukey–Kramer’s post-hoc test.
Student’s t test (two-tailed not paired) was used to compare two
groups. The data were analyzed using Graphpad software
(GraphPad Prism version 5.00, San Diego, CA). A probability
value of 0.05 or less was accepted as significant.Acknowledgments
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